Cancer Chemotherapy and Pharmacology

, Volume 60, Issue 2, pp 275–283

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo

  • Anthony Tumber
  • Laura S. Collins
  • Kamille Dumong Petersen
  • Annemette Thougaard
  • Sanne J. Christiansen
  • Marielle Dejligbjerg
  • Peter Buhl Jensen
  • Maxwell Sehested
  • James W. A. Ritchie
Original Article

Abstract

Purpose

Histone deacetylase inhibitors (HDACi) inhibit the growth of cancer cells, and combinations of HDACi with established chemotherapeutics can lead to synergistic effects. We have investigated effects of PXD101 (HDACi in phase II clinical trials) in combination with 5-fluorouracil, on tumour cell proliferation and apoptosis both in vitro and in vivo.

Experimental design

HCT116 cells were studied using proliferation and clonogenic assays. Synergistic inhibition of proliferation and clonogenicity was determined by incubation with PXD101 and 5-fluorouracil, and analysis using CalcuSyn™ software. The effect of combining PXD101 and 5-fluorouracil on apoptosis was examined in vitro using PARP-cleavage and TUNEL. Finally, the effectiveness of combining PXD101 and 5-fluorouracil in vivo was tested using both HT-29 and HCT116 xenograft models.

Results

Synergistic inhibition of proliferation and clonogenicity was obtained when HCT116 cells were incubated with PXD101 and 5-fluorouracil. 5-fluorouracil combined with PXD101 also increased DNA fragmentation and PARP cleavage in HCT116 cells. Incubation with PXD101 down regulated thymidylate synthase expression in HCT116 cells. In vivo studies, using mouse HT29 and HCT116 xenograft models, showed improved reductions in tumour volume compared to single compound, when PXD101 and 5-fluorouracil were combined.

Conclusions

PXD101 and 5-fluorouracil synergistically combine in their anti-tumour effects against colon cancer cells in vitro and show enhanced activity when combined in vivo. Based on the results presented herein, a rationale for the use of PXD101 and 5-fluorouracil in combination in the clinic has been demonstrated.

Keywords

Histone deacetylase inhibitors Drug combinations Synergy 5-fluorouracil Colorectal cancer 

References

  1. 1.
    Santi DV, Brewer CF (1973) Model studies of thymidylate synthetase Intramolecular catalysis of 5-hydrogen exchange and 5-hydroxymethylation of 1-substituted uracils. Biochemistry 12:2416–2424PubMedCrossRefGoogle Scholar
  2. 2.
    Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthase with 5-Fluorodeoxyuridylate. Biochemistry 13:471–481PubMedCrossRefGoogle Scholar
  3. 3.
    Copur S, Keisuke A, Drake JC, Allegra CJ, Chu E (1995) Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49:1419–1426PubMedCrossRefGoogle Scholar
  4. 4.
    De Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E, Stokke Trond (2004) Molecular characteristics of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic reagent 5-fluorouracil. Int J Oncol 24:1279–1288PubMedGoogle Scholar
  5. 5.
    Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338PubMedCrossRefGoogle Scholar
  6. 6.
    McLaughlin F, La Thangue NB (2004) Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68:1139–1144PubMedCrossRefGoogle Scholar
  7. 7.
    Grozinger CM, Schrieber SL (2002) Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9:3–16PubMedCrossRefGoogle Scholar
  8. 8.
    Hess-Strumpp H (2005) Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84:109–121CrossRefGoogle Scholar
  9. 9.
    Joseph J, Mudduluru G, Anthony S, Vashistha S, Ajitkumar P, Somasundaram K (2004) Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signalling and cancer metastasis by NaB. Oncogne 23:6304–6315CrossRefGoogle Scholar
  10. 10.
    Chiba T, Yokosuka O, Fukai K, Kojima H, Tada M, Arai M, Imazeki F, Saisho H (2004) Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor trichostatin A, on human hepatoma cells. Oncology 66:481–491PubMedCrossRefGoogle Scholar
  11. 11.
    Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by hdac inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151–163PubMedGoogle Scholar
  12. 12.
    Lee H, Lee S, Baek M, Kim HY, Jeoung D-I (2002) Expression profile analysis of trichostatin A in human gastric cells. Biotech Lett 24:377–381CrossRefGoogle Scholar
  13. 13.
    Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anti-cancer drugs targeting DNA. Cancer Res 63:7291–7300PubMedGoogle Scholar
  14. 14.
    Jang ER, Lim S, Lee ES, Jeong G, Kim T-Y, Bang Y-J, Lee J-S (2003) The histone deacetylase inhibitor trichostatin A sensitises estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 23:1–13Google Scholar
  15. 15.
    Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hyroxamic acid. J Cell Biochem 92:223–237PubMedCrossRefGoogle Scholar
  16. 16.
    Plumb JA, Finn PW, Williams RJ, Bandara M, Romero R, Watkins CJ, La Thangue NB, Brown R (2003) Pharmacodynamic response and inhibition of growth of human tumour xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721–728PubMedGoogle Scholar
  17. 17.
    Chou TC (1991) e median-effect principle and the combination index for the quantitation of synergism and antagonism. In: Chou TC, Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic, San Diego, pp 61–102Google Scholar
  18. 18.
    Roed H, Christensen IJ, Vindeloev LL, Spang-Thomsen M, Hansen HH (1987) Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines. Eur J Cancer Clin Oncol 23:177–186PubMedCrossRefGoogle Scholar
  19. 19.
    Duriez PJ, Shah GM (1997) Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75(4):337–349PubMedCrossRefGoogle Scholar
  20. 20.
    Allen RT, Hunter III WJ, Agrawal DK (1997) Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods 37:215–228PubMedCrossRefGoogle Scholar
  21. 21.
    Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, Saisho H (2004) Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatology 41:436–445CrossRefGoogle Scholar
  22. 22.
    Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S (2005) Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69:603–616PubMedCrossRefGoogle Scholar
  23. 23.
    Ruijter AJM, Meinsma RJ, Bosma P, Kemp S, Caron HN, Kuilenburg ABP (2005) Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp Cell Res 309:451–467PubMedCrossRefGoogle Scholar
  24. 24.
    Suzuki T, Miyata N (2005) Non-hydroxymate histone deacetylase inhibitors. Curr Med Chem 12:2867–2880PubMedCrossRefGoogle Scholar
  25. 25.
    Kelly WK, Marks PA (2005) Drug insight: histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2:150–157PubMedCrossRefGoogle Scholar
  26. 26.
    De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–749PubMedCrossRefGoogle Scholar
  27. 27.
    Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES (2003) Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensible for cell cycle inhibition. Mol Cell Biol 23:7719–7731PubMedCrossRefGoogle Scholar
  28. 28.
    Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Can Chem Pharmacol 52:S80–S89CrossRefGoogle Scholar
  29. 29.
    Allen WL, Johnston PG (2005) Role of genomic markers in colorectal cancer treatment. J Clin Oncol 23:4545–4552PubMedCrossRefGoogle Scholar
  30. 30.
    Archer SY, Johnson J, Kim HJ, Ma Q, Mou H, Daesety V, Meng S, Hodin RA (2005) The histone deacetylase inhibitor butyrate downregulates cylcin B1 expression via a p21/WAF−1-dependent mechanism in human colon caner cells. Am J Physiol Gastrointest Liver Physiol 289:G696–G703PubMedGoogle Scholar
  31. 31.
    Tong X, Yin L, Giardina C (2004) Butyrate suppresses Cox−2 activation in colon cancer cells through HDAC inhibition. Biochem Biophys Res Commun 317:463–471PubMedCrossRefGoogle Scholar
  32. 32.
    Hirsch CL, Smith-Windsor EL, Bonham K (2006) Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells. Int J Cancer 118:547–554PubMedCrossRefGoogle Scholar
  33. 33.
    Ocker M, Alajati A, Ganslmayer M, Zopf S, Lüders M, Neureiter D, Hahn EG, Schuppan D, Herold C (2005) The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Re Clin Oncol 131:385–394CrossRefGoogle Scholar
  34. 34.
    Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291–7300PubMedGoogle Scholar
  35. 35.
    Davie JR (1998) Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev 8:173–178PubMedCrossRefGoogle Scholar
  36. 36.
    Marks PA, Richon VM, Rifkind RA (2000) Histone deactetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 15:1210–1216CrossRefGoogle Scholar
  37. 37.
    Grant PA (2001) A tale of histone modifications. Genome Biol 2:reviews0003.1–0003.6Google Scholar
  38. 38.
    Hu J, Colburn NH (2005) Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-κB/p65 DNA binding. Mol Cancer Res 3:100–109PubMedCrossRefGoogle Scholar
  39. 39.
    Lin HY, Chen CS, Lin SP, Weng JR, Chen CS (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397–413PubMedCrossRefGoogle Scholar
  40. 40.
    Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y (2005) Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 14:1223–1230PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Anthony Tumber
    • 1
  • Laura S. Collins
    • 1
  • Kamille Dumong Petersen
    • 2
  • Annemette Thougaard
    • 2
  • Sanne J. Christiansen
    • 2
  • Marielle Dejligbjerg
    • 2
  • Peter Buhl Jensen
    • 2
    • 3
  • Maxwell Sehested
    • 2
    • 4
  • James W. A. Ritchie
    • 1
  1. 1.TopoTarget UK LTDAbingdonUK
  2. 2.TopoTarget A/S, Symbion Science ParkCopenhagenDenmark
  3. 3.Finsen CentreRigshospitaletCopenhagenDenmark
  4. 4.Diagnostic CentreRigshospitaletCopenhagenDenmark

Personalised recommendations